What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Cancer
Christopher T. Ritchlin mainly investigates Psoriatic arthritis, Arthritis, Psoriasis, Internal medicine and Rheumatology.
Christopher T. Ritchlin combines subjects such as Physical therapy and Randomized controlled trial, Surgery with his study of Psoriatic arthritis.
Christopher T. Ritchlin interconnects Psoriasis Area and Severity Index and Adalimumab in the investigation of issues within Surgery.
His research investigates the connection between Arthritis and topics such as Intensive care medicine that intersect with problems in Evidence-based medicine.
His work carried out in the field of Psoriasis brings together such families of science as Pathology, Severity of illness, Rheumatoid arthritis and Ustekinumab.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Placebo, Endocrinology and Peripheral blood mononuclear cell.
His most cited work include:
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial (733 citations)
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial (534 citations)
- Mechanisms of TNF-α– and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis (507 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Psoriatic arthritis, Internal medicine, Psoriasis, Arthritis and Rheumatology.
His Psoriatic arthritis study frequently intersects with other fields, such as Adalimumab.
His Internal medicine research integrates issues from Gastroenterology, Placebo and Surgery.
His Placebo study incorporates themes from Psoriasis Area and Severity Index, Randomized controlled trial and Ustekinumab.
In his study, Infliximab is inextricably linked to Etanercept, which falls within the broad field of Psoriasis.
His Arthritis study combines topics from a wide range of disciplines, such as Intensive care medicine, Rheumatoid arthritis and Pathology.
He most often published in these fields:
- Psoriatic arthritis (61.71%)
- Internal medicine (44.86%)
- Psoriasis (33.14%)
What were the highlights of his more recent work (between 2018-2021)?
- Psoriatic arthritis (61.71%)
- Internal medicine (44.86%)
- Psoriasis (33.14%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Psoriatic arthritis, Internal medicine, Psoriasis, Guselkumab and Placebo.
Christopher T. Ritchlin has included themes like Medical physics and Etanercept in his Psoriatic arthritis study.
In the subject of general Internal medicine, his work in Rheumatology, Arthritis and Adverse effect is often linked to In patient, thereby combining diverse domains of study.
His study explores the link between Arthritis and topics such as Rheumatoid arthritis that cross with problems in Tumor necrosis factor alpha and Lymphatic system.
His biological study spans a wide range of topics, including Disease, MEDLINE, Family medicine and Intensive care medicine.
His work deals with themes such as Psoriasis Area and Severity Index, Gastroenterology, Quality of life, Tildrakizumab and Post-hoc analysis, which intersect with Placebo.
Between 2018 and 2021, his most popular works were:
- Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. (174 citations)
- 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis (85 citations)
- Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial (67 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
Christopher T. Ritchlin spends much of his time researching Psoriatic arthritis, Internal medicine, Psoriasis, Rheumatology and Disease.
He is interested in Enthesitis, which is a field of Psoriatic arthritis.
Christopher T. Ritchlin combines topics linked to Placebo with his work on Internal medicine.
His Psoriasis study integrates concerns from other disciplines, such as Subclinical infection, Family medicine and Clinical trial.
The study incorporates disciplines such as Combination therapy and Ustekinumab in addition to Rheumatology.
His Arthritis study combines topics in areas such as Family aggregation, Natural history of disease, Rheumatoid arthritis and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
